Printer Friendly

LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR

 LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
 LA JOLLA, Calif., March 16 /PRNewswire/ -- LIDAK Pharmaceuticals


(NASDAQ: LDAKU LDAKA) announced today that Daniel J. Paracka was elected as a new director at the annual meeting of shareholders held March 14, 1992.
 Paracka previously held key executive management positions with Rhone Poulenc Rorer Inc. where from 1986 to March 1991 he served as senior vice president finance and chief financial officer. From 1983 to 1986, Paracka served as vice president and controller for the Revlon Health Care Group and Controller of the U.S. Cosmetics Division, for Revlon Inc. Prior to joining Revlon, Paracka held various executive positions with WWG Industries and Champion International. He is currently a senior consultant for The Rand Group, a business and management consulting firm in Rome, Ga. and also serves on the board of directors of Access Pharmaceuticals in Dallas.
 According to David H. Katz, LIDAK's chairman and chief executive officer, "the addition of Mr. Paracka provides an important dimension of pharmaceutical industry expertise to our board."
 Also at this meeting, William N. Jenkins, Katz, Kenneth E. Olson and Sidney N. Towle Jr. were re-elected as directors and an amendment to the company's 1989 stock option plan to increase from 200,000 to 700,000 the number of shares of class A common stock reserved for issuance with respect to options granted under the plan was approved.
 LIDAK Pharmaceuticals is attempting to develop and commercialize pharmaceutical and other commercially significant products for the health care industry. LIDAK is currently focusing its efforts on the commercialization of LIDAKOL(TM) as a treatment for herpes and other indications. In addition the company is developing its Large Multivalent Immunogen technology as potential new therapies against cancer and viral diseases and its Free Fatty Acid technology as a possible clinical diagnostic assay for the prediction, diagnosis and monitoring of cancer and diabetes. Finally, its Human Immune System Reconstituted SCID mouse technology is being used for evaluating new potential anti-AIDS drugs and potential new diagnostic and treatment approaches to cancer.
 -0- 3/16/92
 /CONTACT: Michael H. Lorber, VP and CFO of LIDAK Pharmaceuticals, 619-558-0364/
 (LDAKA LDAKU) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: PER


EH-KJ -- LA014 -- 8353 03/16/92 13:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:372
Previous Article:CANAL CAPITAL DECLARES PREFERRED STOCK DIVIDEND
Next Article:FOXVIDEO ADOPTS COPY PROTECTION IDENTIFICATION PROGRAM
Topics:


Related Articles
LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN
LIDAK PHARMACEUTICALS APPOINTS NEW VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS COMPLETES STAFFING OF ITS CLINICAL DEVELOPMENT ADVISORY PANEL WITH ADDITION OF GALLO
LIDAK ANNOUNCES RETURN OF FORMER CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
LIDAK Pharmaceuticals Adds New Vice President and Reports Drug Development Highlights at Annual Meeting
LIDAK Pharmaceuticals Appoints Susan Yeagley Sullivan As New Chief Financial Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters